A Phase 1 interventional study of PRO 179 and Travatan 0.004 % Ophthalmic Solution in Glaucoma, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-12.
Sponsored by Laboratorios Sophia S.A de C.V. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.
Among the 42 studies testing travoprost in Glaucoma, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 1, and was the 41st registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 89 across the 39 interventional studies. Of the 41 that completed or were terminated, 18 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 42 have an industry lead sponsor. The 10 most frequent:
Laboratorios Sophia S.A de C.V. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.
Laboratorios Sophia S.A de C.V. has 5 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 42 studies testing travoprost in Glaucoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase I clinical study, to evaluate the safety and tolerability of the ophthalmic solution PRO-179 compared with Travatan®, on the ocular surface of clinically healthy subjects.
Goals: To evaluate the safety and tolerability of the formulation PRO-179 manufactured by Sophia Laboratories S.A. of C.V. on the ocular surface of clinically healthy subjects.
Hypothesis:The ophthalmic solution PRO-179 presents a profile of safety and tolerability similar to Travatan® in healthy subjects.
Methodology: Clinical trial Phase I, controlled, of parallel groups, double blind, with randomization.
Number of patients: n= 24, 12 subjects per group (both eyes). Main inclusion criteria: Clinically healthy subjects.
duration: 10 days.
Duration of subject in the study: 15 to 22 days.
Adverse events will be reported and cataloged based on the MedDRA dictionary and will be reported to the corresponding regulatory entity.
The sponsor will carry out monitoring or quality visits to the research sites where it corroborates the information of the source documents and will contrast them with the information presented in the electronic CRF. Electronic case report forms will be evaluated by the clinical research associate and the clinical team of the sponsor (medical ophthalmologist researcher and pharmacologist of clinical safety).
Statistical methodology:
The data will be expressed with measures of central tendency: mean and standard deviation for the quantitative variables. The qualitative variables will be presented in frequencies and percentages. The statistical analysis will be carried out by means of the Mann-Whitney U test for the quantitative variables for the difference between the groups. The difference between the qualitative variables will be analyzed by means of X2 (Chi2) or Fisher's exact. An alpha ≤ 0.05 will be considered significant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Blood count (BH): , erythrocytes, hematocrit, total leukocytes, , mean corpuscular volume and mean corpuscular hemoglobin.
Liver function tests (PFH): and Alanine Aminotransferase, total , direct and indirect.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosage: 1 drop every 24 hours, at night, in both eyes.
Drug: PRO 179
Dosage: 1 drop every 24 hours, at night, in both eyes.
Drug: Travatan 0.004 % Ophthalmic Solution
* Generic name: Travoprost * Distinctive denomination: Bristrio® (PRO-179) * Active principles: Travoprost 0.004%. * Pharmaceutical form: Ophthalmic solution * Presentation: multi-dose dropper bottle, 2.5 milliliters. * Prepared by: Sophia Laboratories, S.A. of C.V. * Description of the solution: transparent solution, free of visible particles. * Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.
Also known as: PRO-179, Bristrio®, Travoprost 0.004% ophthalmic solution
* Generic name: Travoprost * Distinctive denomination: Travatan® * Active ingredients: Travoprost 0.004% * Pharmaceutical form: Ophthalmic solution. * Presentation: multi-dose dropper bottle, 2.5 milliliters. * Prepared by: Alcon Laboratories Inc. * Description of the solution: transparent solution, free of visible particles. * Consult information to prescribe.
Also known as: Travoprost 0.004% ophthalmic solution
Number of Participants With Adverse Events
primary security variable the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent. it will be evaluated by the number of reported cases per group.
Time frame: during the 14 days of evaluation, including the safety call (day 14).
Eye Comfort Index
It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).
Time frame: will be evaluated at the end of the treatment, at the final visit (day 11)
Number of Eyes With Epithelial Defects by Grade
The epithelial defects will be evaluated by means of two stains, lissamine green and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.
Time frame: will be evaluated at the end of the treatment, at the final visit (day 11)
Visual Ability
The visual capacity variable will be reported using as a unit of measure a fraction, this is taken from a visual test with the Snellen primer, it is a Nominal type variable. where the optimal vision is 20/20 and the worst vision is 20/200, higher values represent a worst vision. The result of the Snellen chart has equivalents in an international logarithmic system called Logmar (logarithm of the minimum angle of resolution) for better understanding. Snellen Scale: 20/200, 20/100, 20/50, 20/40, 20/30, 20/25, 20/20, 20/15, 20/12, 20/10. Snellen / LogMAR equivalences: 20/200= 1.0, 20/100=0.7, 20/50=0.4, 20/40=0.3, 20/30=0.2, 20/25=0.1, 20/20=0.0, 20/15=0.13, 20/12=0.2, 20/10=-0.3, etc.
Time frame: will be evaluated at the end of the treatment, at the final visit (day 11)
Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade
Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very Light / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.
Time frame: will be evaluated at the end of the treatment, at the final visit (day 11)
Number of Eyes of Chemosis
The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent.
Time frame: will be evaluated at the end of the treatment, at the final visit (day 11)
Changes in Intraocular Pressure
the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg
Time frame: will be evaluated at the end of the treatment, at the final visit (day 11)
| Milestone | PRO-179 | Travatan® |
|---|---|---|
| Started | 12 | 12 |
| Completed | 11 | 12 |
| Not completed | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
primary security variable the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent. it will be evaluated by the number of reported cases per group.
| Participants | PRO-179 | Travatan® |
|---|---|---|
| Number of Participants With Adverse Events | 10 | 11 |
It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).
| score on a scale | PRO-179 | Travatan® |
|---|---|---|
| Eye Comfort Index | 26.61 ± 11.3 | 28.97 ± 7.9 |
The epithelial defects will be evaluated by means of two stains, lissamine green and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.
| eyes | PRO-179 | Travatan® |
|---|---|---|
| Green lissamine grade 0 | 22 | 23 |
| Green lissamine grade 1 | 0 | 1 |
| Green lissamine grade 2 | 0 | 0 |
| Green lissamine grade 3 | 0 | 0 |
| Green lissamine grade 4 | 0 | 0 |
| Fluorescein grade 0 | 20 | 20 |
| Fluorescein grade 1 | 2 | 4 |
| Fluorescein grade 2 | 0 | 0 |
| Fluorescein grade 3 | 0 | 0 |
| Fluorescein grade 4 | 0 | 0 |
The visual capacity variable will be reported using as a unit of measure a fraction, this is taken from a visual test with the Snellen primer, it is a Nominal type variable. where the optimal vision is 20/20 and the worst vision is 20/200, higher values represent a worst vision. The result of the Snellen chart has equivalents in an international logarithmic system called Logmar (logarithm of the minimum angle of resolution) for better understanding. Snellen Scale: 20/200, 20/100, 20/50, 20/40, 20/30, 20/25, 20/20, 20/15, 20/12, 20/10. Snellen / LogMAR equivalences: 20/200= 1.0, 20/100=0.7, 20/50=0.4, 20/40=0.3, 20/30=0.2, 20/25=0.1, 20/20=0.0, 20/15=0.13, 20/12=0.2, 20/10=-0.3, etc.
| LogMAR | PRO-179 | Travatan® |
|---|---|---|
| Visual Ability | 0.0 ± 0 | 0.0 ± 0 |
Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very Light / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.
| eyes | PRO-179 | Travatan® |
|---|---|---|
| Normal (0) | 14 | 16 |
| Very mild (1) | 2 | 2 |
| Mild (2) | 6 | 6 |
| Moderate (3) | 0 | 0 |
| Severe (4) | 0 | 0 |
The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent.
| eyes | PRO-179 | Travatan® |
|---|---|---|
| Number of Eyes of Chemosis | 0 | 0 |
the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg
| mmHg | PRO-179 | Travatan® |
|---|---|---|
| Changes in Intraocular Pressure | 11.95 ± 1.6 | 10.71 ± 1.5 |
Collected over Adverse events were evaluated for about 2 months and one week until the last follow-up call of the last subject.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PRO-179 | 0/12 (0%) | 1/12 (8.3%) | 10/12 (83.3%) |
| Travatan® | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Event | PRO-179 | Travatan® |
|---|---|---|
| ocular hypotonyEye disorders | 1/12 | 0/12 |
| Event | PRO-179 | Travatan® |
|---|---|---|
| red eyeEye disorders | 10/12 | 9/12 |
| ocular burningEye disorders | 4/12 | 6/12 |
| Dry eyeGeneral disorders | 4/12 | 3/12 |
| eye itchingEye disorders | 2/12 | 3/12 |
| eye painEye disorders | 2/12 | 2/12 |
| photophobiaEye disorders | 2/12 | 1/12 |
| tearingEye disorders | 0/12 | 2/12 |
| headacheNervous system disorders | 0/12 | 1/12 |
| eyelid painEye disorders | 0/12 | 1/12 |
| ocular hypotonyEye disorders | 1/12 | 1/12 |
| Age, Continuous(years) | PRO-179 | Travatan® | Total |
|---|---|---|---|
| Mean | 28.2 ± 8.0 | 24.7 ± 4.6 | 26.3 ± 6.6 |
| Sex: Female, Male(Participants) | PRO-179 | Travatan® | Total |
|---|---|---|---|
| Female | 4 | 8 | 12 |
| Male | 8 | 4 | 12 |
| Race/Ethnicity, Customized(Participants) | PRO-179 | Travatan® | Total |
|---|---|---|---|
| Latin | 12 | 12 | 24 |
| Region of Enrollment(participants) | PRO-179 | Travatan® | Total |
|---|---|---|---|
| Mexico | 12 | 12 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Jul 2019, 2 months.
Results were first posted in Dec 2019, 5 months after primary completion.
Of 18 phase 1 interventional studies under Glaucoma, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost
Laboratorios Sophia S.A de C.V. →